8-K
Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
ATAI
Ataibeckley Inc.
A clinical-stage biopharmaceutical company developing psychedelic-inspired treatments for mental health, including BPL-003, a short-acting nasal spray for hard-to-treat depression. It was born in 2025 from the merger of atai Life Sciences and Beckley Psytech, the latter named after Beckley Park, the centuries-old English estate of the Feilding family. Its lead therapy is a synthetic form of a compound found in toad venom.
CUSIP: 04650F1011 holder
Dec 30, 2025 — Reclassified from ATAI Life Sciences NV (1:1)